Diarrhea News and Research

Latest Diarrhea News and Research

FDA grants accelerated approval of Perjeta for people with HER2-positive early stage breast cancer

The U.S. Food and Drug Administration granted accelerated approval of a Perjeta- (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.

2 Oct 2013

FDA grants accelerated approval to Perjeta for neoadjuvant treatment of breast cancer

The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.

1 Oct 2013

Diabetes puts you at increased risk of flu-related complications

There are certain groups of people who are at risk of serious flu complications each year, including those with diabetes.

30 Sep 2013

FDA expands Hizentra administration options for people with primary immunodeficiency

CSL Behring announced today that the U.S. Food and Drug Administration has expanded the administration options for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, to include dosing once every two weeks (biweekly) for people diagnosed with primary immunodeficiency.

28 Sep 2013

Immunologic checkpoint inhibitor shows promise in malignant mesothelioma

Tremelimumab, one of a new class of immunomodulatory monoclonal antibodies, has shown encouraging clinical activity and acceptable tolerability in patients with chemotherapy-resistant malignant mesothelioma, results of a single-arm phase II study show.

27 Sep 2013

Icotinib matches gefitinib in NSCLC second or third line

Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.

26 Sep 2013

Ten health care innovations could save lives of mothers and children

Ten health care innovations, if brought to scale immediately in low-resource countries, could have the potential to save the lives of some 1.2 million mothers and children in 2015.

26 Sep 2013

Sulfasalazine drug does not reduce diarrhea for patients receiving pelvic radiation therapy: Study

Sulfasalazine, a drug commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area a Mayo Clinic-led study has found.

24 Sep 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes.

24 Sep 2013

Clean water and growth of children: an interview with Dr Alan Dangour

Growth in children is known to be directly affected by two critical factors: food intake and incidence of disease. It is known that access to good quality water, improved sanitation and enhanced hygiene (WASH) practices lead to decreased levels of infectious disease in children. We were interested to know whether this decline in disease would lead to improvements in child growth.

23 Sep 2013

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use recommended Xofigo (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

20 Sep 2013

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn's disease patients.

18 Sep 2013

Researchers identify starting points for preventing diarrheal disease outbreaks in remote Africa

Using a simple survey tool, a team of researchers has done what complex studies have failed to do -- provide data that identifies starting points for preventing diarrheal disease outbreaks in at least one region of Africa.

18 Sep 2013

Understanding essential role of gut microbes in immune system

A new understanding of the essential role of gut microbes in the immune system may hold the key to dealing with some of the more significant health problems facing people in the world today, Oregon State University researchers say in a new analysis.

17 Sep 2013

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer.

17 Sep 2013

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Amgen today announced the publication of a biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer.

12 Sep 2013

Study finds low doses of vancomycin to be effective in treating serious C-difficile infection

Clostridium difficile infection (CDI) treatment in a hospital setting using low dose oral vancomycin showed similar effectiveness compared to high dose, according to a new study by researchers at Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University.

12 Sep 2013

MicroBiome Therapeutics' NM504 eliminates diarrhea caused by metformin in type 2 diabetes patient

MicroBiome Therapeutics LLC, a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a potentially important new application for its lead product, NM504. NM504 is in clinical development to promote healthy blood glucose levels and metabolic fitness in prediabetic and diabetic populations.

11 Sep 2013

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found.

9 Sep 2013

Diarrhea News and Research

Latest Diarrhea News and Research

FDA grants accelerated approval of Perjeta for people with HER2-positive early stage breast cancer

FDA grants accelerated approval to Perjeta for neoadjuvant treatment of breast cancer

Diabetes puts you at increased risk of flu-related complications

FDA expands Hizentra administration options for people with primary immunodeficiency

Immunologic checkpoint inhibitor shows promise in malignant mesothelioma

Icotinib matches gefitinib in NSCLC second or third line

Ten health care innovations could save lives of mothers and children

Sulfasalazine drug does not reduce diarrhea for patients receiving pelvic radiation therapy: Study

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Clean water and growth of children: an interview with Dr Alan Dangour

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

Researchers identify starting points for preventing diarrheal disease outbreaks in remote Africa

Understanding essential role of gut microbes in immune system

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Study finds low doses of vancomycin to be effective in treating serious C-difficile infection

MicroBiome Therapeutics' NM504 eliminates diarrhea caused by metformin in type 2 diabetes patient

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in